Inhibikase Therapeutics, Inc.
IKT
$1.84
$0.084.55%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.51% | -12.74% | -109.98% | -16.50% | -6.67% |
| Total Depreciation and Amortization | 90.55% | 92.42% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -53.24% | 4.12% | 5,243.58% | 382.08% | -42.51% |
| Change in Net Operating Assets | -64.85% | 217.72% | -251.94% | 662.42% | -118.27% |
| Cash from Operations | -35.84% | 23.24% | -9.52% | 3.43% | -30.71% |
| Capital Expenditure | 100.00% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -53.28% | 154.35% | -1,634.45% | -0.67% | 176.79% |
| Cash from Investing | -53.25% | 154.32% | -1,634.45% | -0.67% | 176.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 54,671.70% | -94.34% | 708.25% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 200.00% |
| Cash from Financing | -- | -- | 54,671.70% | -94.39% | 784.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -74.62% | -69.50% | 2,657.63% | -396.41% | 110.76% |